MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2024 International Congress

    A new phenotype-genotype correlation for FIG4 gene and Parkinson’s disease

    I. Boura, G. Xiromerisiou, I A. Giannopoulou, P. Mitsias, C. Spanaki (HERAKLION, Greece)

    Objective: We present a patient with atypical Parkinson’s disease (PD), carrying a homozygous missense mutation of FIG4. Background: FIG4 is involved in endosomal-lysosomal trafficking and…
  • 2024 International Congress

    Clinical Profile of Motor Complications in Parkinson’s Disease Patients at A National Tertiary Hospital In Indonesia

    Y. Rapri, A. Jody, A. Tiksnadi, D. Tunjungsari (Depok, Indonesia)

    Objective: To analyse factors associated with motor complications in Parkinson's disease at a national tertiary referral hospital in Indonesia. Background: As Parkinson's disease progresses, levodopa…
  • 2024 International Congress

    Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model

    A. Centner, N. Lipari, C. Budrow, G. Mcmanus, I. Sandoval, K. Tseng, F. Manfredsson, C. Bishop (Binghamton, USA)

    Objective: Levodopa (LD) is the standard treatment for Parkinson’s Disease (PD) despite risk of LD-induced dyskinesia (LID) development within a decade of treatment. Serotonergic (5-HT)…
  • 2024 International Congress

    Basal ganglia theta oscillation as a predictor of levodopa-induced dyskinesias

    M. Wilken, L. Granda, I. Cruz Varela, M. Rossi, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

    Objective: To investigate the temporal and spatial relationship between local field potential (LFP) changes and dyskinesia development. Background: Levodopa-induced dyskinesias (LID) are an important burden…
  • 2024 International Congress

    The Differences in the Perception of Parkinson’s Disease-related Motor Complications between Patients and Physicians

    T. Tezuka, R. Okochi, Y. Sakai, T. Nukariya, S. Okusa, Y. Nihei, J. Nakahara, M. Seki (Tokyo, Japan)

    Objective: This study aimed to evaluate the differences in the perception of Parkinson’s disease (PD)-related motor complications by utilizing questionnaires answered by both PD patients…
  • 2024 International Congress

    Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis

    G. Bolner, Y. Rossi, E. de Almeida, F. de Oliveira, V. Müller, L. Barbosa Lima, A. Rossato, G. Guindani Maia, A. Hilbig (Porto Alegre, Brazil)

    Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…
  • 2024 International Congress

    Clinical, Neurophysiological, and Biological Insights into Levodopa-Induced Dyskinesias

    B. Angeloni, A T. Cimmino, R. Di Iorio, P. Calabresi, G. Di Lazzaro (Rome, Italy)

    Objective: The aim of this study was to determine the clinical, neurophysiological and biological features of Parkinson's Disease (PD) patients with L-Dopa-induced dyskinesias (LIDs). Background:…
  • 2024 International Congress

    Correlation Between Mild Cognitive Impairment and Levodopa Induced Dyskinesia in Parkinson’s Disease Patients

    A. Mansour, A. Radwan, S. Ibrahim, N. Elkhayat (Cairo, Egypt)

    Objective: The aim of this study is to compare the level of mild cognitive impairment in Parkinson’s disease patients with and without levodopa-induced dyskinesia. Additionally,…
  • 2024 International Congress

    Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study

    MR. Luquin, C. Martin, I. Tegel, I. Pijuan, C. Moreno (Pamplona, Spain)

    Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…
  • 2024 International Congress

    Abnormal Subthalamic Oscillations as Potential Biomarkers for Identifying the Dyskinesia-Inducing Region within the Subthalamic Nucleus in Parkinson’s Disease

    J. Li, J. Wei, X. Jia, Y. Liang, Y. Zhang (beijing, China)

    Objective: To investigate the characteristics of local field potentials (LFPs) associated with the STN region that elicit stimulation-induced dyskinesia (SID) in PD patients. Background: Approximately 50%…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 44
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley